Plant Name: Sapium haematospermum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ALPI; TDP1; BLM; AKR1B1; TNKS; PARP1; TNKS2; POLB; | |
| GAA; | |
| CA2; CA12; CA7; CA4; | |
| ESR1; ESR2; | |
| ALOX5; ALDH2; | |
| TP53; NFKB1; | |
| RAB9A; LMNA; NPC1; MAPT; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.173E-09 | 2.366E-05 | AKR1B1, CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, ESR1, NPC1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.528E-09 | 2.707E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.215E-09 | 2.707E-05 | CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.185E-08 | 4.301E-05 | ALPI, BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, PARP1, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.067E-08 | 1.887E-04 | CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.193E-07 | 2.886E-04 | ALOX5, CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.841E-07 | 4.010E-04 | CYP19A1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.334E-07 | 4.620E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.625E-07 | 5.314E-04 | CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.335E-07 | 6.453E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.235E-06 | 1.262E-03 | CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0065007; biological regulation | GO:0042592; homeostatic process | 2.206E-06 | 1.847E-03 | AKR1B1, BLM, CA12, CA2, CA7, ESR1, GAA, NPC1, PARP1, POLB, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.176E-06 | 1.847E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.974E-06 | 2.880E-03 | CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 4.233E-06 | 2.880E-03 | AKR1B1, BLM, CA2, CYP1B1, NPC1, PARP1, TP53 |
| CC | GO:0044464; cell part | GO:0005635; nuclear envelope | 4.057E-06 | 2.880E-03 | ALOX5, LMNA, NPC1, PARP1, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.281E-06 | 3.108E-03 | CYP19A1, CYP1B1, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.523E-06 | 3.464E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 7.729E-06 | 3.659E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 8.686E-06 | 3.860E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0009628; response to abiotic stimulus | 1.058E-05 | 4.518E-03 | AKR1B1, BLM, CA2, LMNA, MAPT, NFKB1, PARP1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.303E-05 | 5.256E-03 | TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.303E-05 | 5.256E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0010647; positive regulation of cell communication | 1.390E-05 | 5.459E-03 | AKR1B1, CA2, CA7, CYP19A1, CYP1B1, NFKB1, PARP1, THPO, TNKS, TNKS2, TP53 |
| BP | GO:0023052; signaling | GO:0023056; positive regulation of signaling | 1.447E-05 | 5.459E-03 | AKR1B1, CA2, CA7, CYP19A1, CYP1B1, NFKB1, PARP1, THPO, TNKS, TNKS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.971E-05 | 6.957E-03 | AKR1B1, CYP19A1, CYP1B1, ESR1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.981E-05 | 6.957E-03 | CA2, CA7, NPC1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.439E-05 | 8.046E-03 | CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 2.984E-05 | 9.697E-03 | AKR1B1, CYP1B1, NFKB1, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.372E-09 | 9.460E-07 | CA12; CA2; CA4; CA7 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.987E-05 | 1.122E-03 | CYP2C9; CYP2D6; ALOX5; CYP2C19 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.768E-05 | 1.450E-03 | PARP1; LMNA; TP53; NFKB1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.132E-05 | 1.450E-03 | ALOX5; CYP1B1; CYP19A1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.787E-05 | 2.212E-03 | CYP2C9; ALOX5; CYP2C19 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.528E-04 | 2.249E-03 | ESR1; NFKB1; ESR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.347E-04 | 2.249E-03 | CYP2C9; CYP2D6; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.820E-04 | 3.187E-03 | CYP2C9; ALDH2; GAA; ALOX5; AKR1B1; ALPI; CYP2C19; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.592E-04 | 2.249E-03 | CYP2C9; CYP2D6; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.247E-04 | 2.822E-03 | CYP2C9; CYP1B1; CYP2C19 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 9.873E-04 | 7.853E-03 | RAB9A; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.186E-03 | 1.865E-02 | POLB; TP53; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.859E-03 | 2.849E-02 | MAPT; TP53; NFKB1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.044E-04 | 7.485E-03 | CYP2C9; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.530E-03 | 1.017E-02 | ALDH2; CYP1B1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 6.052E-03 | 2.849E-02 | POLB; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.111E-03 | 2.212E-02 | TP53; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.611E-04 | 7.485E-03 | GAA; AKR1B1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 3.300E-03 | 1.865E-02 | ALDH2; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.040E-04 | 5.177E-03 | CA2; CA4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.006E-03 | 2.571E-02 | TP53; NFKB1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.240E-03 | 8.761E-03 | ALDH2; AKR1B1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.191E-03 | 1.865E-02 | CYP1B1; CYP19A1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.353E-03 | 3.196E-02 | TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.903E-03 | 3.400E-02 | CYP1B1; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 6.881E-03 | 3.110E-02 | TP53; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 8.170E-03 | 3.297E-02 | TP53; NFKB1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.042E-03 | 7.853E-03 | POLB; PARP1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 9.027E-03 | 3.400E-02 | ESR1; ESR2 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 8.004E-03 | 3.297E-02 | PARP1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.263E-02 | 4.334E-02 | ALOX5; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.263E-02 | 4.334E-02 | TP53; ESR1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.304E-02 | 4.334E-02 | TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.304E-02 | 4.334E-02 | TP53; NFKB1 |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 1.367E-02 | 4.412E-02 | NPC1; GAA |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.585E-02 | 4.974E-02 | TP53; NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Melanoma | C43 | PARP1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | PARP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; NFKB1; ESR1; ESR1; PARP1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1; ALDH2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ALDH2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |